NVO Overview
Upcoming Projects (NVO)
Executed Projects (NVO)
-
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2025
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 30, 2025 at 12:23 PM EDT -
A Second Look: Discussing the potential of UBT251, a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1, GIP and glucagon, recently acquired by Novo Nordisk
Tickers: NVO, LLY
Executed On: Apr 10, 2025 at 11:30 AM EDT -
Discussing the potential of UBT251, a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1, GIP and glucagon, recently acquired by Novo Nordisk
Tickers: NVO, LLY
Executed On: Apr 03, 2025 at 10:00 AM EDT -
Exploring the Factor XI landscape with a focus on NOVO/Anthos' abelacimab and Regeneron's REGN9933/7508
Tickers: NVO, REGN, Anthos Therapeutics
Executed On: Mar 06, 2025 at 12:00 PM EST -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2025
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 27, 2025 at 11:06 AM EST -
Investigating the potential of liraglutide, a GLP-1 agonist from Novo Nordisk as a treatment for obesity in children younger than 12 years of age
Ticker: NVO
Executed On: Jan 23, 2025 at 03:00 PM EST -
A look at the data from the SURMOUNT-5 phase 3b head-to-head weight loss trial of Zepbound (tirzepatide) compared to Wegovy (semaglutide).
Tickers: LLY, NVO
Executed On: Jan 15, 2025 at 10:30 AM EST -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 24, 2024 at 04:56 PM EDT -
Investigating the potential of liraglutide, a GLP-1 agonist from Novo Nordisk as a preventative treatment of Alzheimer's disease.
Ticker: NVO
Executed On: Oct 01, 2024 at 04:00 PM EDT -
Discussing the potential of INV-202 (Monlunabant), a CB1 antagonist currently in development by Novo Nordisk for weight loss
Tickers: NVO, LLY, CRBP
Executed On: Aug 20, 2024 at 10:30 AM EDT -
Digging into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Tickers: LLY, NVO
Executed On: Aug 14, 2024 at 01:00 PM EDT -
Discussing the SURMOUNT-OSA phase 3 clinical trial of tirzepatide in patients with obstructive sleep apnea and obesity
Tickers: LLY, NVO
Executed On: Aug 06, 2024 at 10:00 AM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic July 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Aug 01, 2024 at 10:42 AM EDT -
Exploring the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy for obesity and type 2 diabetes
Tickers: GUTS, NVO, LLY
Executed On: Jul 19, 2024 at 02:30 PM EDT -
A Second Opinion: Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jul 09, 2024 at 04:30 PM EDT -
Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jun 27, 2024 at 10:30 AM EDT -
A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 14, 2024 at 11:00 AM EDT -
Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 13, 2024 at 02:40 PM EDT -
Discussing the recent data from the FLOW trial and the effects of Novo Nordisk's semaglutide on chronic kidney disease in patients with type 2 diabetes.
Ticker: NVO
Executed On: Jun 06, 2024 at 11:00 AM EDT -
Discussing the landscape of Novo Nordisk's (NVO) Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with Type 2 diabetes
Ticker: NVO
Executed On: May 24, 2024 at 10:00 AM EDT -
Discussing the CB1 axis to treat obesity, including CBR-913 and nimicimab
Tickers: CRBP, SKYE, NVO
Executed On: May 06, 2024 at 03:00 PM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 18, 2024 at 03:17 PM EDT -
A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Tickers: NVO, LLY
Executed On: Mar 22, 2024 at 09:30 AM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 22, 2024 at 01:24 PM EST -
Discussing the impact of GLP-1 agonists on patient eligibility for bariatric surgeries and the need for new surgical systems
Tickers: ISRG, NVO, LLY, MDT
Executed On: Dec 08, 2023 at 01:15 PM EST -
A Payor Perspective: Discussing reimbursement for GLP-1 drugs based on cardiovascular benefits with a focus on the SELECT trial
Tickers: NVO, LLY
Executed On: Dec 06, 2023 at 02:00 PM EST -
Discussing the potential of semaglutide in chronic kidney disease and Novo Nordisk's recent decision to stop the kidney outcomes trial, FLOW based on interim analysis
Ticker: NVO
Executed On: Nov 15, 2023 at 04:30 PM EST -
Quarterly Survey: Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 26, 2023 at 04:59 PM EDT -
A Second Look: Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with an endocrinologist
Tickers: NVO, LLY
Executed On: Sep 13, 2023 at 11:00 AM EDT -
A Second Look: Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 28, 2023 at 03:00 PM EDT -
Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with a cardiologist
Tickers: NVO, LLY, AZN
Executed On: Aug 22, 2023 at 02:15 PM EDT -
Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 11, 2023 at 10:30 AM EDT -
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jul 25, 2023 at 05:46 PM EDT -
Discussing private and commercial payor reimbursement strategies in the US for obesity drugs such as semaglutide and tirzepatide
Tickers: NVO, LLY
Executed On: Jul 20, 2023 at 11:00 AM EDT -
Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023
Tickers: LLY, NVO, AZN
Executed On: Apr 12, 2023 at 02:43 PM EDT -
Checking in with a prescriber of Novartis' Rybelsus (semaglutide) as a first-line therapy for adults with type 2 diabetes.
Ticker: NVO
Executed On: Jan 23, 2023 at 04:30 PM EST -
Digging into the clinical landscape of Type 2 Diabetes and the potential of Novo Nordisk's once weekly insulin Icodec
Ticker: NVO
Executed On: Nov 02, 2022 at 12:00 PM EDT -
A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, NVO, MDGL
Executed On: Aug 01, 2022 at 12:00 PM EDT -
Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, MDGL, NVO
Executed On: Jul 13, 2022 at 03:00 PM EDT -
A look at the pending PDUFA of tirzepatide and how it may compare to Rybelsus (semaglutide) and the Type 2 diabetes space as a whole
Tickers: LLY, NVO
Executed On: Apr 21, 2022 at 04:00 PM EDT
Expired Projects (NVO)
-
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016 -
Understanding the potential of Novo Nordisk's (NVO) Tresiba in treatment of type 2 diabetes
Ticker: NVO
Execute By: Feb 05, 2016
Upcoming & Overdue Catalysts (NVO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (NVO)
-
PDUFA for Novo Nordisk's (NVO) N8-GP in Hemophilia A expected February 26, 2019.
Ticker: NVO
Occurred on: Feb 19, 2019 -
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017 -
CHMP Recommends Addition of SWITCH 1 and SWITCH 2 Data to Novo's (NVO) Tresiba
Ticker: NVO
Occurred on: Mar 24, 2017 -
CHMP Recommends Novo's (NVO) Refixia for Approval in Hemophilia B
Ticker: NVO
Occurred on: Mar 24, 2017 -
European Commission Approves Novo's (NVO) Fast Acting Insulin Fiasp
Ticker: NVO
Occurred on: Jan 10, 2017 -
Novo Nordisk expects to file semaglutide for regulatory review in the US and EU in the fourth quarter of 2016
Ticker: NVO
Occurred on: Dec 05, 2016 -
Novo Nordisk (NVO) receives US FDA approval for Xultophy 100/3.6
Ticker: NVO
Occurred on: Nov 21, 2016 -
Novartis's (NVO) Midostaurin (PKC412) Granted Priority Review by FDA for Acute Myeloid Leukemia (AML) and Mastocytosis
Ticker: NVO
Occurred on: Nov 14, 2016 -
Novo Nordisk's (NVO) NDA for Faster-Acting Insulin Rejected by FDA
Ticker: NVO
Occurred on: Oct 11, 2016 -
Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba label
Ticker: NVO
Occurred on: Sep 23, 2016 -
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Ticker: NVO
Occurred on: May 24, 2016 -
Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial
Ticker: NVO
Occurred on: Apr 28, 2016 -
Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
Ticker: NVO
Occurred on: Mar 04, 2016 -
Novo Nordisk (NVO) Expects to Release Data from SWITCH-1 Trial Evaluating Tresiba in Type 1 Diabetes Patients in Q1 2016
Ticker: NVO
Occurred on: Feb 23, 2016 -
Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes
Ticker: NVO
Occurred on: Feb 23, 2016
Strategic Initiatives (NVO)
